EQS-Adhoc

Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)

EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS) 26-Oct-2023 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

 

 

 

Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS)

 

OSAKA, Japan, October 26, 2023 - Takeda (TSE:4502/NYSE:TAK) today announced the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2024, as below.

 

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2024

 (millions JPY)

	Revenue	Operating profit	Profit before income taxes	Net profit attributable to owners of the Company	Basic earnings per share
Original Forecast (A)*	3,840,000	349,000	185,000	142,000	90.75 JPY
Revised Forecast (B)	3,980,000	225,000	70,000	93,000	59.45 JPY
Discrepancy (B-A)	140,000	(124,000)	(115,000)	(49,000)	―
Change %	3.6%	(35.5)%	(62.2)%	(34.5)%	―

^* Announced on May 11, 2023.